Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Gen T-cell Engaging Multispecific Antibodies June 23, 2026
FAILED TRIAL: Ph 3 TRIDENT trial of TTFields did not meet primary endpoint of significant OS increase in GBM patients when used early June 23, 2026
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for NPX200 and NPX900 June 23, 2026
Ph 3 DAREON®-Lung-1 in SCLC, DAREON®-NEC-1 in extrapulmonary NEC, and Beamion LUNG-3 trials in HER2-mutant NSCLC initiated June 23, 2026
Positive Updated Results from RAMP 205 of Avutometinib, Defactinib and SOC chemo in 1L Metastatic Pancreatic Cancer Announced June 23, 2026
Voro Therapeutics and Alloy Therapeutics Enter Strategic Research Collaboration to Advance Next-Gen Masked TCE Therapeutics June 23, 2026
Antengene Announces Exclusive License Agreement with K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE June 23, 2026
The third U.S. clinical site in Ph 2 THIO-101 expansion trial of ateganosine enrolling patients in 3L NSCLC June 23, 2026
First Patient Dosed in TARGET-D 201 Ph 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Metastatic Pancreatic Cancer June 23, 2026
Multiple Complete Responses Reported After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer June 23, 2026
Ph 3 STELLAR-303 Trial of Zanzalintinib + Tecentriq in Metastatic CRC Patients didn’t meet the dual primary endpoint of OS improvement in the liver mets patients June 23, 2026
UAE IND Approval obtained for NEO212 Following Successful Ph 1 Completion, Advancing Toward Global Ph 2 Development June 23, 2026
IND application for HLX3902 approved in China for treatment of metastatic CRPC and solid tumors June 23, 2026
Positive Pre-IND Feedback from Received US FDA for CLD-401; IND enabling studies to continue with IND submission targeted by end of 2026 June 23, 2026
Japan Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of R/R DLBCL Announced June 23, 2026
